News for WuXi Biologics (Cayman) Inc. (2269N.MX)

Summary On March 3, 2025, WuXi Biologics (Cayman) Inc (WXXWY), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announce

Summary WuXi Biologics (Cayman) Inc (WXXWY), a prominent global Contract Research, Development, and Manufacturing Organization (CRDMO), announced on February 26

Summary WuXi Biologics (Cayman) Inc (WXXWY), a prominent global Contract Research, Development, and Manufacturing Organization (CRDMO), announced on February 18

Summary WuXi Biologics (Cayman) Inc (WXXWY), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced on February 10,

Summary WuXi Biologics (Cayman) Inc (WXXWY), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced on January 6, 20

Summary WuXi Biologics (Cayman) Inc (WXXWY), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced on January 2, 20

Summary On December 12, 2024, WuXi Biologics (Cayman) Inc (WXXWY), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), anno

Revenue: RMB8.5 billion, a 1% increase; non-COVID revenue grew by 7.7%.Adjusted Net Profit: Down 13% due to timing issues with milestone revenue.Adjusted Gross

WuXi Biologics is expected to report a more modest pace of top-line expansion and lower profit margins in fiscal 2024. See why WXIBF stock is a Hold.

WuXi Biologics (Cayman) Inc. (OTCPK:WXXWY) Q2 2024 Earnings Conference Call August 22, 2024 8:30 AM ETCompany ParticipantsLina Fan - Senior Vice President,...

The following slide deck was published by WuXi Biologics (Cayman) Inc.

Revenue increased by 1.0% YoY to RMB 8,574.2 million

WuXi Biologics seems to be moderating its pace of investments in the US market. Read why I have a mixed view of WXIBF stock as a potential investment.

It is also planning to increase its bets on India, which accounted for 7% of its portfolio in March

Tesla, Zoom and Pelotonare among 50 corporate winners from the COVID-19 pandemic to lose US$1.5 trillion in market value. Read more.

/PRNewswire/ -- The biologics CDMO market size is estimated to grow by USD 13.26 billion from 2022 to 2027, at a CAGR of 13.97%, according to a recent market...

Baron Emerging Markets Fund gained 2.68% (Institutional Shares) during the first quarter of 2023, while its principal benchmark Index, the MSCI EM Index, returned 3.96%.

Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing.

Vanguard Health Care Fund VGHCX portfolio, holdings, 13f and stock news. Updated: 2023-05-01 portfolio, holdings, 13F and news. Updated: 2023-05-01